Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508416 | 0.84 | STK17B (0.49) | STK17BSTK17AAAK1TRPV1 | |
| SCHEMBL6509221 | 0.78 | STK17B (0.42) | STK17BSTK17AAAK1BTK | |
| SCHEMBL31380404 | 0.75 | STK17B (0.53) | STK17BSTK17AATR | |
| SCHEMBL29784722 | 0.74 | AAK1 (0.53) | AAK1SERPINE1 | |
| SCHEMBL15092577 | 0.74 | AAK1 (0.53) | AAK1SERPINE1 | |
| SCHEMBL15092576 | 0.74 | AAK1 (0.53) | AAK1SERPINE1 | |
| SCHEMBL24619149 | 0.73 | TNF (0.38) | STK17BSTK17AAAK1 | |
| SCHEMBL16794337 | 0.72 | TRPV1 (0.42) | STK17BSTK17AAAK1BTKTRPV1 | |
| SCHEMBL27063663 | 0.72 | BTK (0.37) | BTK | |
| SCHEMBL24619111 | 0.72 | STK17B (0.37) | STK17BSTK17AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2005-08-04 | — | — | US | disclosed |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | DAVIS JEREMY MARTIN (GB) | 2003-11-13 | — | — | US | disclosed |
| US-6600037-B1 | The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis. | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
| EP-1222175-A1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | Celltech R&D Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001029009-A1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | CELLTECH R&D LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FLT4, FGFR1 | STK17B 3074/4885STK17A 3227/4885AAK1 2762/4885 |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | STK17B 3540/4885STK17A 3642/4885AAK1 1970/4885 |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | STK17B 3535/4885STK17A 3647/4885AAK1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.